Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Treatment of Epiretinal Membranes With Ranibizumab (LERM)

This study has been completed.
Information provided by (Responsible Party):
Queen's University Identifier:
First received: November 9, 2010
Last updated: January 12, 2016
Last verified: January 2016
The purpose of this study is to determine whether intraocular injection of ranibizumab decreases the retinal thickness in patients with epiretinal membranes and reduces associated symptoms.

Condition Intervention
Epiretinal Membrane
Drug: intravitreal ranibizumab

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Prospective Pilot Study of Lucentis for Epiretinal Membranes: the LERM Study

Resource links provided by NLM:

Further study details as provided by Queen's University:

Primary Outcome Measures:
  • Evidence of improvement measured by optical coherence tomography [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Distance visual acuity (ETDRS) [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
  • Near visual acuity (Snellen) [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
  • Subjective change in symptoms [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
  • Amsler grid improvement [ Time Frame: 3 and 6 months ] [ Designated as safety issue: No ]
  • Quality of life improvement [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 11
Study Start Date: November 2010
Study Completion Date: January 2012
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Ranibizumab
('intravitreal ranibizumab' )
Drug: intravitreal ranibizumab
monthly injections x3 +/- 2nd series of 3
Other Name: Lucentis


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • symptomatic idiopathic epiretinal membrane

Exclusion Criteria:

  • vision worse than 6/18 and fit for surgery
  • prior vitreoretinal surgery or injection
  • diabetes
  • any past or current form of retinal vein occlusion or neovascularization
  • age-related macular degeneration
  • other condition causing significant limitation of visual potential
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01238393

Canada, Ontario
Queen's University, Hotel Dieu Hospital
Kingston, Ontario, Canada, K7L 5G2
Sponsors and Collaborators
Queen's University
Principal Investigator: Jeffrey Gale, MD Queen's University
  More Information

Responsible Party: Queen's University Identifier: NCT01238393     History of Changes
Other Study ID Numbers: OPTH-092-10 
Study First Received: November 9, 2010
Last Updated: January 12, 2016
Health Authority: Canada: Ethics Review Committee

Additional relevant MeSH terms:
Epiretinal Membrane
Retinal Diseases
Eye Diseases
Immunologic Factors
Physiological Effects of Drugs
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors
Antineoplastic Agents processed this record on October 28, 2016